Page 719 - Read Online

Page 14 of 15 Wang et al. Hepatoma Res 2020;6:61 I http://dx.doi.org/10.20517/2394-5079.2020.55

52. Zuccolo J, Unruh TL, Deans JP. Efficient isolation of highly purified tonsil B lymphocytes using RosetteSep with allogeneic human red
blood cells. BMC Immunol 2009;10:30.
53. Hayes GM, Busch R, Voogt J, Siah IM, Gee TA, et al. Isolation of malignant B cells from patients with chronic lymphocytic leukemia (CLL)
for analysis of cell proliferation: validation of a simplified method suitable for multi-center clinical studies. Leuk Res 2010;34:809-15.
54. Vona G, Sabile A, Louha M, Sitruk V, Romana S, et al. Isolation by size of epithelial tumor cells: a new method for the
immunomorphological and molecular characterization of circulatingtumor cells. Am J Pathol 2000;156:57-63.
55. Vona G, Estepa L, Beroud C, Damotte D, Capron F, et al. Impact of cytomorphological detection of circulating tumor cells in patients
with liver cancer. Hepatology 2004;39:792-7.
56. Desitter I, Guerrouahen BS, Benali-Furet N, Wechsler J, Janne PA, et al. A new device for rapid isolation by size and characterization of
rare circulating tumor cells. Anticancer Res 2011;31:427-41.
57. Dong Y, Skelley AM, Merdek KD, Sprott KM, Jiang C, et al. Microfluidics and circulating tumor cells. J Mol Diagn 2013;15:149-57.
58. Nagrath S, Sequist LV, Maheswaran S, Bell DW, Irimia D, et al. Isolation of rare circulating tumour cells in cancer patients by microchip
technology. Nature 2007;450:1235-9.
59. Stott SL, Hsu CH, Tsukrov DI, Yu M, Miyamoto DT, et al. Isolation of circulating tumor cells using a microvortex-generating
herringbone-chip. Proc Natl Acad Sci U S A 2010;107:18392-7.
60. Karabacak NM, Spuhler PS, Fachin F, Lim EJ, Pai V, et al. Microfluidic, marker-free isolation of circulating tumor cells from blood
samples. Nat Protoc 2014;9:694-710.
61. Sarioglu AF, Aceto N, Kojic N, Donaldson MC, Zeinali M, et al. A microfluidic device for label-free, physical capture of circulating
tumor cell clusters. Nat Methods 2015;12:685-91.
62. Qian W, Zhang Y, Chen W. Capturing cancer: emerging microfluidic technologies for the capture and characterization of circulating tumor
cells. Small 2015;11:3850-72.
63. Guo W, Sun YF, Shen MN, Ma XL, Wu J, et al. Circulating tumor cells with stem-like phenotypes for diagnosis, prognosis, and
therapeutic response evaluation in hepatocellular carcinoma. Clin Cancer Res 2018;24:2203-13.
64. de Boer CJ, van Krieken JH, Janssen-van Rhijn CM, Litvinov SV. Expression of Ep-CAM in normal, regenerating, metaplastic, and
neoplastic liver. J Pathol 1999;188:201-6.
65. Yamashita T, Forgues M, Wang W, Kim JW, Ye Q, et al. EpCAM and alpha-fetoprotein expression defines novel prognostic subtypes of
hepatocellular carcinoma. Cancer Res 2008;68:1451-61.
66. Nicolazzo C, Gradilone A, Loreni F, Raimondi C, Gazzaniga P. EpCAM(low) circulating tumor cells: gold in the waste. Dis Markers
2019;2019:1718920.
67. Xu W, Cao L, Chen L, Li J, Zhang XF, et al. Isolation of circulating tumor cells in patients with hepatocellular carcinoma using a novel
cell separation strategy. Clin Cancer Res 2011;17:3783-93.
68. Li J, Chen L, Zhang X, Zhang Y, Liu H, et al. Detection of circulating tumor cells in hepatocellular carcinoma using antibodies against
asialoglycoprotein receptor, carbamoyl phosphate synthetase 1 and pan-cytokeratin. PLoS One 2014;9:e96185.
69. Hamaoka M, Kobayashi T, Tanaka Y, Mashima H, Ohdan H. Clinical significance of glypican-3-positive circulating tumor cells of
hepatocellular carcinoma patients: a prospective study. PLoS One 2019;14:e0217586.
70. Court CM, Hou S, Winograd P, Segel NH, Li QW, et al. A novel multimarker assay for the phenotypic profiling of circulating tumor cells
in hepatocellular carcinoma. Liver Transpl 2018;24:946-60.
71. Guo W, Yang XR, Sun YF, Shen MN, Ma XL, et al. Clinical significance of EpCAM mRNA-positive circulating tumor cells in
hepatocellular carcinoma by an optimized negative enrichment and qRT-PCR-based platform. Clin Cancer Res 2014;20:4794-805.
72. Kalinich M, Bhan I, Kwan TT, Miyamoto DT, Javaid S, et al. An RNA-based signature enables high specificity detection of circulating
tumor cells in hepatocellular carcinoma. Proc Natl Acad Sci U S A 2017;114:1123-8.
73. Liu YK, Hu BS, Li ZL, He X, Li Y, et al. An improved strategy to detect the epithelial-mesenchymal transition process in circulating
tumor cells in hepatocellular carcinoma patients. Hepatol Int 2016;10:640-6.
74. Wan S, Kim TH, Smith KJ, Delaney R, Park GS, et al. New labyrinth microfluidic device detects circulating tumor cells expressing
cancer stem cell marker and circulating tumor microemboli in hepatocellular carcinoma. Sci Rep 2019;9:18575.
75. Hu B, Yang XR, Xu Y, Sun YF, Sun C, et al. Systemic immune-inflammation index predicts prognosis of patients after curative resection
for hepatocellular carcinoma. Clin Cancer Res 2014;20:6212-22.
76. Wang BL, Tian L, Gao XH, Ma XL, Wu J, et al. Dynamic change of the systemic immune inflammation index predicts the prognosis of
patients with hepatocellular carcinoma after curative resection. Clin Chem Lab Med 2016;54:1963-9.
77. Schulze K, Gasch C, Staufer K, Nashan B, Lohse AW, et al. Presence of EpCAM-positive circulating tumor cells as biomarker for
systemic disease strongly correlates to survival in patients with hepatocellular carcinoma. Int J Cancer 2013;133:2165-71.
78. Kelley RK, Magbanua MJ, Butler TM, Collisson EA, Hwang J, et al. Circulating tumor cells in hepatocellular carcinoma: a pilot study of
detection, enumeration, and next-generation sequencing in cases and controls. BMC Cancer 2015;15:206.
79. Yu JJ, Xiao W, Dong SL, Liang HF, Zhang ZW, et al. Effect of surgical liver resection on circulating tumor cells in patients with
hepatocellular carcinoma. BMC Cancer 2018;18:835.
80. von Felden J, Schulze K, Krech T, Ewald F, Nashan B, et al. Circulating tumor cells as liquid biomarker for high HCC recurrence risk
after curative liver resection. Oncotarget 2017;8:89978-87.
81. Shen J, Wang WS, Zhu XL, Ni CF. High epithelial cell adhesion molecule-positive circulating tumor cell count predicts poor survival
of patients with unresectable hepatocellular carcinoma treated with transcatheter arterial chemoembolization. J Vasc Interv Radiol
2018;29:1678-84.